The assessment of the patient with systemic sclerosis

Autoimmunity Reviews

Volumn 2, Issue 6, 2003, Pages 370-376

  Valentini, Gabriele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Activity; Assessment; Damage; Subsets; Systemic sclerosis

Indexed keywords

AUTOANTIBODY;

ANTIBODY LABELING; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; FEASIBILITY STUDY; FIBROSIS; HUMAN; LABORATORY TEST; LUNG ALVEOLITIS; MEDICAL ASSESSMENT; MEDICAL PRACTICE; MULTIPLE ORGAN FAILURE; PREDICTION; PROGNOSIS; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; SCORING SYSTEM; SERODIAGNOSIS; SKIN DISEASE; SYSTEMIC SCLEROSIS; TREATMENT PLANNING;

EID: 0141638417     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(03)00057-0     Document Type: Review

References (30)

1. Seibold J.R. Scleroderma. Ruddy S., Harris E.D. Jr, Sledge C.B. Kelley's Textbook of Rheumatology. Sixth ed. 2001;1211-1239 W.B. Saunders Company, Philadelphia.
2. Leroy E.C., Black C.M., Fleichmajer R., et al. Scleroderma (systemic sclerosis). Classification, subset and pathogenesis. J Rheumatol. 15:1988;202-205.
3. Giordano M., Valentini G., Migliaresi S., et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 13:1986;911-916.
4. Ferri C., Valentini G., Cozzi F., et al. Systemic sclerosis. Demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine. 81:2002;139-153.
5. Scussel-lonzetti L., Joyal F., Raynauld J.-P., et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine. 81:2002;154-167.
6. Masi A.T., Rodnan G.P., Medsger T.A., et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23:1980;581-590.
7. Medsger T.A. Comment on scleroderma criteria cooperative study. Black C.M., Myers A.R. Current Topics in Rheumatology. Systemic Sclerosis (Scleroderma). 1985;16-17 Gower Medial Publishing, New York.
8. LeRoy E.C., Medsger T.A. Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 28:2001;1573-1576.
9. Valentini G. Classification of systemic sclerosis. Clin Dermatol. 12:1994;217-223.
10. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am. 22:1996;709-735.
11. Weiner E.S., Earnshaw W.C., Senecal J.L., et al. Clinical association of anticentromere antibodies and antibodies to topoisomerase I. Arthritis Rheum. 31:1988;378-385.
12. Harvey G.R., Butts S., Rands A.L., et al. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol. 117:1999;395-402.
13. Clements P., Lachenbruch P., Siebold J., et al. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 22:1995;1281-1285.
14. Steen V.D., Medsger T.A. Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 44:2001;2828-2837.
15. Symmons D.P.M. (1995) Disease assessment indices: activity, damage and severity. In: Silman A.J., Symmons D.P.M. (Eds.), Classification and Assessment of Rheumatic Diseases, Part I. Baillier's Clin Rheumatol Vol. 9, pp. 267-285.
16. Owens G.R., Follansbee W.P. Cardiopulmonary manifestations of systemic sclerosis. Chest. 91:1987;118-127.
17. Medsger T.A. Jr. Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol. 12:2000;545-548.
18. Clements P.J., Peter J.B., Agopian M.S., et al. Elevated serum levels of solubile interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited sclerodermia: effects of chlorambucil. J Rheumatol. 17:1990;908-910.
19. Black C.M., Silman A.J., Herrick A.I., et al. Interferon-alfa does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomised, double-blind, placebo-controlled study. Arthritis Rheum. 42:1999;299-305.
20. Valentini G., Della Rossa A., Bombardieri S., et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 60:2001;592-598.
21. Medsger T.A., Silman A.J., Steen V.D., et al. A disease severity scale for systemic sclerosis. Development and testing. J Rheumatol. 26:1999;2159-2167.
22. Steen V.D., Medsger T.A. The value of health assessment questionnaire and special patient generated scales to demonstrated change in systemic sclerosis patients over time. Arthritis Rheum. 40:1997;1984-1991.
23. Clements P.J., Wong W.K., Hurwitz E.L., et al. The disability index of the health assessment questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum. 44:2001;653-661.
24. Medsger T.A., Masi A.T., Rodnan G.P., et al. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 75:1971;369-376.
25. Bryan C., Knight C., Black C.M., Silman A.J. Prediction of five-year survival following presentation with scleroderma. Development of a sample model using three disease factors at first visit. Arthritis Rheum. 42:1999;2660-2665.
26. Della Rossa A., Valentini G., Bombardieri S., et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis. 60:2001;585-591.
27. Valentini G., Medsger T.A. Jr., Silman A.J., & Bombardieri S. (Eds.) (2003). The assessment of the patient with systemic sclerosis. Clin Exp Rheumatol, 21 (suppl 29), In press.
28. White B., Bauer E.S., Goldsmith L.A., et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. American College of Rheumatology Committee on design and outcomes in clinical trials in systemic sclerosis (scleroderma). Arthritis Rheum. 38:1995;351-360.
29. Merkel P.A., Herlyn K., Martin R.W., et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 46:2002;2410-2420.
30. Merkel P.A., Clements P.J., Reveille J.D., et al. (2003) Current Status of Outcome Measure Development for Clinical Trials in Systemic Sclerosis. Report from OMERACT 6. J Rheumatol, In press.